Details for Patent: 9,018,192

Which drugs does patent 9,018,192 protect, and when does it expire?

Patent 9,018,192 protects ATRIPLA and is included in one NDA.

This patent has sixty-one patent family members in twenty-seven countries.

Summary for Patent: 9,018,192

Title:	Unitary pharmaceutical dosage form
Abstract:	In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Inventor(s):	Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
Assignee:	Gilead Sciences Inc
Application Number:	US14/050,714
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,018,192
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,018,192

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	9,018,192					TREATMENT OF HIV-1 INFECTION IN ADULTS
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No	9,018,192					TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

International Family Members for US Patent 9,018,192

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	054060
Argentina	054511
Austria	E419839
Australia	2006257794